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INTRODUCTION 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease, 
involving the colon. 
Long believed to be a disease of the young, 10-30% of patient living 
with inflammatory bowel disease are over the age of 60, either having aged 
with UC or developing it as an older adult. 
The natural history of late onset ulcerative colitis, above 65 years of 
age, is not well defined. Disease course, response to therapy, prognosis and 
outcomes comparing populations with late and early onset of disease have 
been investigated in several studies with conflicting results [1, 2, 3, 4].  
Epidemiologic studies have revealed that late onset UC, defined as 
onset > 60 years of age, is observed in 8 – 11% of all UC patients [1, 2, 4] 
thus, together with the rise of the overall incidence of UC, a sizeable 
number of patients can be expected to be diagnosed in the upcoming 
decades. No data are available from randomized clinical trials on treatment-
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specific issues in elderly patients [5], namely response to therapies or safety. 
The available data are currently based on retrospective analyses. Based on 
these studies, late onset UC seems to be characterized by a milder disease 
course, better response to steroids [6], lower rates of disease progression, 
and lower need for immunomodulators (IMM) or biologics (BIO) [1, 7]. 
However, the less frequent use of IMM or BIO in elderly compared to 
younger populations may also be related to safety concerns that may limit 
their use by physicians and not to disease severity alone. Currently, more 
frequent severe infections and less favourable outcomes are reported in 
elderly patients treated with anti-TNF therapy [8, 9], as well as more 
frequent adverse events in patients on thiopurines, for example skin cancer 
or lymphoproliferative diseases [10, 11]. It is also well documented that 
elderly UC patients have more disease-related hospitalizations compared to 
younger patients [12, 13] and have a higher post-surgical morbidity and 
mortality [14, 15, 16, 17, 18]. 
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1.1. Epidemiology  
Approximately 10–15% of IBD in the USA is diagnosed after the 
age of 60. This incidence rate is conservative, since the true incidence of 
older-onset IBD can be difficult to determine due to greater difficulty in 
diagnosing these patients and the methodology of current epidemiological 
studies [3]. 
Older-onset UC is more common than CD, with rates higher in 
elderly men than women. The worldwide incidence of IBD varies by region, 
typically highest in Westernised nations and lowest in developing countries. 
The US incidence UC is 6–8/100 000/year in individuals > 60 years old. 
Among older patients worldwide, the incidence UC is 3–11/100 000 in 
Europe and 0.1–1/100 00 in Asia [1]. In Asia, approximately 15% of newly 
diagnosed IBD cases are > 60 years of age. When examining the largest 
cohort of older-onset IBD patients to date, being > 60 years old at diagnosis 
1/8 of all incident UC cases. IBD incidence decreases with each subsequent 
8		
decade after age 60, with 25% of individuals being diagnosed in their 70s 
and 10% being diagnosed in their 80s [19]. 
Though the incidence and prevalence of adult IBD may be stable in 
several developed countries, the rates are increasing in Asia and parts of 
Europe among both genders and across all age groups, with the exception of 
the very young and those >80. The underlying reasons for this trend may be 
a combination of increased urbanisation, greater awareness of IBD among 
providers, better access to care and colonoscopy and advancements in 
diagnostic methods [20]. 
Because mortality in IBD is only very mildly elevated and the 
disease is most often diagnosed in the young, its overall prevalence among 
older individuals is expected to grow substantially [20]. 
 
1.2. Pathophysiology  
Ulcerative colitis is believed to develop in genetically susceptible 
individuals who develop an aberrant immune system that reacts 
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inappropriately to gut organisms and their by-products. Environmental 
factors can play a role at various stages in this process but have not been 
specifically studied in older UC patients.  
Genetics appear to be less important in older-onset UC, as opposed 
to patients diagnosed at an earlier age. In UC 13% of patients < 17 years old 
had a family history of IBD, compared with only 3% of those > 60 years old 
[1]. 
When exposed to antigens in the gut, the intestine has to distinguish 
innocuous from detrimental antigens. This distinction is aided by an intact 
and functional intestinal epithelium, the innate immune system and an 
adaptive immune system, consisting of primarily B and T cells, which 
respond to foreign antigens. In ageing, a reduction in the number of naive T 
cell precursors and an impaired ability of virtual memory T cells contribute 
to reduced T cell responses [21]. 
This age-related immunosenescence is associated with changes in 
intestinal microbiota composition, increasing the risk of an aberrant immune 
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system and development of IBD. 
The effect of ageing on the human gut microbiota and its balance 
with the host’s immune system, may be related to the progression of 
geriatric syndromes and diseases in the elderly population. Major 
physiological changes impact on the composition and function of the 
intestinal microbiota in older adults, including decreased intestinal motility, 
prolonged transit time, faecal retention, nutritional changes associated with 
decreased sense of smell and taste, dental decay, and dysphagia. 
Furthermore, the increased use of medications including laxatives and 
antibiotics also affects the gut microbiota.  
The composition of bacteria changes in the elderly, with a decrease 
in anaerobes [e.g. Bifidobacteria], in both abundance and species diversity 
and an increase in facultative anaerobes, including streptococci, 
staphylococci, enterococci, and enterobacteria, a balance that is associated 
with IBD. Moreover, a geriatric syndrome characterised by restricted 
physiological reserves and an impaired resistance to stressors, may be 
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associated with a more profound gut dysbiosis. Van Tongeren et al. found 
that frail elderly have up to 26-fold less anaerobes and -fold more 
enterobacteria than healthy or less frail elderly [21]. 
 
1.3. Differenzial diagnosis & clinical presentation 
Establishing a definitive diagnosis of UC in older adults can be challenging. 
Illness in older adults is often complicated by the physical changes of 
ageing, associated comorbidities and atypical presentations. The 
unreliability of physical examination findings and lack of sensitivity of 
laboratory testing are commonly encountered and further complicate the 
diagnostic process. In addition, even with advancements in diagnostic tools, 
intestinal inflammation from various causes can mimic UC [Table 1] [21]. 
The clinical presentation of UC upon diagnosis differs between older and 
younger patients [Table 2]. When compared with younger patients, older-
onset UC more frequently presented with isolated colonic inflammation, 
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patients tend to have less isolated proctitis, but more left colon inflammation 
and present with less rectal bleeding and abdominal pain [21].  
Disease Clinical characteristics Distinguishing findings 
 
Infectious colitis 
 
Diarrhoea (with possible 
blood), fever 
Positive stool studies, 
Pseudomembranes on 
endoscopy (Clostridium 
difficile infection)  
NSAID-induced 
enterocolitis 
Diarrhoea (with possible 
blood), iron deficiency 
anaemia, obstruction, 
perforation 
Diaphragm-like small 
bowel stricture, elderly 
especially at risk 
 
Ischaemic colitis 
 
Acute onset of abdominal 
pain, followed by bloody 
diarrhoea 
Segmental area of injury, 
rectal sparing, abrupt 
transition between normal 
and affected mucosa 
Segmental colitis 
associated with 
diverticula [SCAD] 
Bloody stools diarrhoea, 
abdominal pain 
Inflammation only in and 
around diverticulum  
 
 
Radiation colitis 
Bloody diarrhoea, 
urgency, tenesmus occur 
weeks to years after 
abdominal/pelvic 
radiation 
Histologically: fibrosis and 
capillary telengiectasia 
 
 
Diversion colitis 
Occurs in surgically 
diverted bowel loop, most 
asymptomatic, but can 
have abdominal pain and 
bloody/mucous discharge 
Histologically: prominent 
lymphoid hyperplasia 
 
Solitary rectal ulcer 
syndrome 
 
Rectal bleeding, straining, 
pelvic fullness 
Histologically, thickened 
mucosal layer and crypt 
architectural distortion, 
smooth muscle and 
collagen replace lamina 
propria 
 
Table 1. Differential diagnosis of ulcerative colitis in the elderly [21]. 
 
Overall, at diagnosis, older-onset UC may be associated with fewer signs 
and symptoms, with the pattern most likely related to the location of disease 
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and the decreased intestinal inflammatory burden [21]. 
Clinical manifestation Elderly Younger adults 
Overall symptoms More subtle More flagrant 
UC symptoms Less abdominal pain and 
rectal bleeding 
More abdominal pain 
and rectal bleeding  
Disease location More left-side colonic 
inflammation, less 
isolated proctitis 
More extensive colitis 
Disease course Localization of disease 
more lickely to remain 
stable 
Localization of disease 
more lickely to extend 
Extra-intestinal 
manifestations 
Less common More common 
 
Table 2. Clinical manifestations of UC in elderly versus younger adults 
[21]. 
 
1.4. Treatment 
The approach to UC treatment includes three main goals:  
1] induce and maintain remission;  
2] prevent disease-related complications;  
3] improve quality of life and minimise adverse events.  
Treatment strategies are based on the location and severity of 
inflammation and take into consideration the perceived natural history of the 
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disease [21]. 
Older-onset UC typically is not associated with disease progression [Table 
2]. In a French cohort with follow-up over at least 2 years, only 3% of UC 
patients with proctitis and 5% of UC patients with left-sided colitis, 
progressed to extensive colitis. Overall, the extent of UC remained stable in 
84% of patients. Over time, 0–17% of patients > 60 years old have 
progression of their disease, at rates lower than those seen in younger 
patients [1]. 
Determining the most appropriate therapeutic approach in the elderly 
is challenging due to multiple factors. First, there is a lack of drug efficacy 
trials in older patients, as most are excluded, particularly from trials with 
immunosuppressive agents. Also, appropriate clinical endpoints are unclear 
in the elderly. Additionally, multimorbidity increases the complexity of 
medical therapy decisions and polypharmacy elevates the risk of non-
compliance and drug interactions [22]. 
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2. METHODS  
2.1. Aim of the study 
The aim of the Assessment of IBD in Geriatric patients and Evolution of 
Disease (AGED)- study was to assess the differences in disease severity and 
extension at UC onset in three different age groups and to compare the disease 
course and patterns in the following 3 years from diagnosis. 
 
2.2. Study design 
The AGED-study is a retrospective multicentre study conducted by the 
Italian Group for the study of IBD (IG-IBD) in 20 referral centres across Italy. 
Consecutive subjects diagnosed with UC between 2005 and 2010 according to 
established endoscopic and histological criteria [23], with disease onset at the age 
of 65 years or above (target group, elderly) were included. For each patient of the 
target group, one consecutive patient diagnosed with UC between age 40 and 64 
years (adults), matched for sex, and two additional sex-matched patients 
diagnosed before age 40 years (young patients) in the same study period were 
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included. To analyse the disease characteristics at onset and first-line treatment, 
all data concerning diagnosis, clinical and endoscopic activity, medications and 
surgery had to be available in each centre database for the first year. To analyse 
the disease course according to patterns, the need for any treatment or surgery and 
data on response to therapy in the follow-up period, only the data from regularly 
assessed patients (at least two visits in the follow-up period) were included for a 
global follow-up time of 3 years from diagnosis. Subjects with undefined IBD or 
Crohn’s disease or microscopic colitis were also excluded. 
The following data were collected: time to diagnosis, defined as interval 
between symptom onset and definite diagnosis, smoking status (current, former, 
and ex-smokers), haemoglobin and C-reactive protein (CRP) levels at diagnosis, 
extension of disease at diagnosis according to the Montreal classification [24] and 
severity of disease according to the endoscopic Mayo subscore [25] at onset and 
during the follow-up. In addition, data on previous and/or concomitant 
extraintestinal manifestations (EIM) and concomitant diseases, expressed as the 
Charlson Comorbidity Index (CCI) [26], were collected. In the follow-up period, 
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therapy with mesalazine (5-ASA), steroids (systemic steroids or low 
bioavailability steroids; l.b.s.), IMM therapy (thiopurines or methotrexate), anti-
TNFs (BIO) and surgery rates were reviewed. Response to steroids in the first 
year was defined as no further prescription of steroids, or therapy with IMM, BIO, 
or surgery in the subsequent 12 months, after the first course of steroids. Response 
to IMM was defined as no further prescription of steroids, BIO or UC-related 
surgery after start of therapy with IMM or no discontinuation of IMM due to side 
effects. Moreover, the study population was stratified according to disease pattern 
at the end of the observation period as follows:  
Pattern 1) disease onset and subsequent mild or no activity 
Pattern 2) relapsing behaviour (more than one flare/year with remission 
time > 3 months) 
Pattern 3) chronically active disease defined as no remission lasting more 
than 3 months.  
Assessment of the disease patterns was performed according to Henriksen 
[27], excluding patients colectomized within the first year or patients lost to 
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follow-up after the first year. Data concerning the onset of UC and response to 
steroids were analyzed and compared among the 3 study groups, whereas the 
follow-up data over 3 years were analyzed by disease pattern and compared 
between pattern 1 and pooled patterns 2 and 3.  
Parameters with more than 5% data lacking were excluded from analysis.  
The study design was approved by the IG-IBD scientific committee and, 
subsequently, approved by the local ethics committee of the coordinating centre 
(Messina, Protocol n. 02/2013; February 25th, 2013). All data were collected and 
handled anonymously according to the national law on data protection. 
 
2.3. Data presentation and statistics  
Numerical data were expressed as means ± standard deviation (SD), 
medians [min-max] or proportions (%) as appropriate. The chi square test, 
Fisher’s Exact test or the Log-likelihood Ratio were used to compare categorical 
variables. Continuous variables were compared using the Kruskal-Wallis H test 
with the Dunn’s test for multiple comparisons. 
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Logistic regression models (univariate and multivariate) were constructed 
to identify significant risk factors for the need for immunosuppression or to 
undergo colectomy. 
To compare the cumulative risk of treatment with immunomodulators or 
biologics and to be colectomized between the three groups in patients with pattern 
1 or with pattern 2-3, a Kaplan-Meier survival estimate was sought, accompanied 
by the log rank test of equality over strata. 
All comparisons utilized a two-sided significance level of 0.05. Data 
analysis was carried out with SPSS Statistics for Windows, version 17.0, Chicago: 
SPSS Inc.  
A p value <0.05 was considered statistically significant. 
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3. RESULTS 
A total of 1091 patients distributed in the three age groups were included 
in the final analysis. Demographic data and baseline characteristics are 
summarized in Table 3 a-b. Median time to diagnosis was significantly longer in 
young patients compared to adults (p<0.0001), but not different compared to the 
elderly. Former smokers were more prevalent (p<0.0001) in adults and in elderly. 
Conversely, never smokers were more prevalent (p<0.002) in young patients than 
in the other two groups. No difference was found for current smokers. The CCI 
was significantly higher in the elderly and adults compared to younger patients 
(p<0.0001). Diabetes (24%, 15%, and 1%, respectively in the elderly, adults, and 
young patients), heart disease (myocardial infarction, congestive heart failure; in 
15%, 6%, and 0.5%), lung disease (obstructive lung disease, asthma; in 12%, 7%, 
and 0.6%), chronic kidney disease (in 6%, 4%, and 0.2%), neuro-psychiatric 
disorders (in 5%, 1%, and 0.2%), and chronic liver diseases (mostly HCV-related 
diseases; in 0.7%, 3%, and 0.8%) were the most common comorbidities observed 
in the study population.  
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Table 3 a. General and clinical data of the three patient groups at diagnosis. 
Medians [min-max], means±SD and proportions (%) are presented as appropriate.  
Extraintestinal manifestations of IBD at maximal follow-up: bone and join includes 
osteopenia, osteoporosis and spondylarthropthies; skin includes pyoderma 
gangrenosum, erythema nodosum and psoriasis; liver includes primary biliary 
cirrhosis and primary sclerosing cholangitis; eye includes uveitis and episcleritis; 
other includes thrombosis and vasculitis. 
 
 
 elderly 
≥65 yrs 
n=283 
adults 
40-64 yrs 
n=285 
young 
patients 
<40 yrs 
n=523 
p-value 
Age at diagnosis (years) 71.4 ± 5.6 55.2 ± 9.4 26.9 ± 8.5 - 
Male 161 (56%) 187 (66%) 280 (54%) - 
Time to diagnosis 
(months) 
1 [0-96] 0 [0-48] 2 [0-168] <0.0001 
Haemoglobin at diagnosis 
(g/dl) 
11.7 ± 1.9 12.2 ± 1.9 12.3 ± 1.9 0.174 
Smoking habits; n (%) 
active 
ex-smokers 
never smokers  
 
18 (6.8%) 
95 (35.7%)  
153 (57.5%) 
 
19 (7.0%) 
102 (37.4%)  
152 (55.6%)  
 
56 (10.9%) 
82 (16.0%) 
375 (73.1%) 
 
 
0.063 
<0.0001 
<0.0001 
 
Charlson comorbidity  
index  
CCI 0, n(%) 
CCI 1, n(%) 
CCI 2, n(%) 
CCI 3+, n(%) 
 
187 (66.8%) 
65 (23.2%)  
26 (9.3%)  
2 (0.7%) 
 
217 (75.3%)  
59 (20.5%)  
11 (3.9%)  
1 (0.3%) 
 
505 (96.6%) 
18 (3.4%) 
0 (0%) 
0 (0%) 
 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Extraintestinal 
manifestations; n (%) 
Bone and joint 
Skin 
Liver 
Eye  
Other 
16 (5.7%) 
7 (2.5%) 
5 (1.8%) 
0 (0%) 
2 (0.7%) 
2 (0.7%) 
13 (4.6%) 
10 (3.5%) 
2 (0.7%) 
0 (0%) 
1 (0.3%) 
0 (0%) 
23 (4.4%) 
7 (1.3%) 
3 (0.6%) 
7 (1.3%) 
3 (0.6%) 
3 (0.6%) 
- 
0.555 
0.021 
0.004 
0.964 
0.082 
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 elderly 
≥65 yrs 
n=283 
adults 
40-64 yrs 
n=285 
young patients 
   <40 yrs 
    n=523 
p-value 
Montreal, n(%) 
E1 
E2 
E3 
 
36 (12.7%) 
158 (55.8%) 
89 (31.5%) 
 
    32 (11.6%) 
    172 (60.7 %) 
    81 (28.8 %) 
 
60 (11.5%) 
272 (52.0%) 
191 (36.5%) 
0.185 
Disease severity, n(%) 
Mayo 1 
Mayo 2 
Mayo 3 
 
75 (26.5%)  
146 (51.6%)  
62 (21.9%) 
 
    90 (31.6%) 
     160 (56.1%) 
    35 (12.3%) 
 
 
87 (16.6%) 
338 (64.6 %) 
98 (18.8 %) 
<0.0001 
 
Table 3 b. Disease extension according to the Montreal classification and disease 
severity according to the endoscopic Mayo subscore at diagnosis in the three 
study groups.	
 
Although not included in CCI calculation, hypertension was the most 
frequent disease found in 43%, 29%, and 2% of patients [Figure 1]. 
 
	
Figure 1. Prevalence of comorbidities in the 3 age groups. 
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Before diagnosis of UC, extraintestinal manifestations (EIM) were similar 
in the 3 groups (3.2% in the elderly, 3.8% in adults, and 3.3% in young patients) 
increasing to 5.7%, 4.6% and 4.4% at 3 years, respectively. The frequency of liver 
disease differed between the three gropus (p 0.0004). In particular, young patients 
showed a higher number of hepatic EIM, such as primary biliary cirrhosis (1/523) 
and primary sclerosing cholangitis (6/523), compared to the elderly and adults. 
Skin related EIM were more frequent in the elderly (p=0.021). 
 
3.1. Extension and severity of UC at diagnosis.  
Extension of disease according to the Montreal classification at the 
moment of diagnosis was similar in the 3 groups [Table 3 b]. Conversely, 
endoscopic activity at diagnosis differed between the 3 groups (p<0.0001). Mild 
activity was significantly more frequent in the elderly and adults than in young 
subjects. 
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Moderate disease activity (Mayo 2) was the most frequent presentation of 
disease in all age groups (from 51.0% to 64.6%), but was significantly more 
prevalent in young patients than in the elderly. Severe disease at onset was less 
frequent in adults compared with the elderly.  
 
3.2. Disease pattern 
The relative distribution of disease patterns is given in Figure 2.  
	
Figure 2. Distribution of disease patterns in UC diagnosed ≥65 yrs (n=232; 
elderly), between 40-64 yrs (n=266; adults), and subjects diagnosed <40 yrs 
(n=498; young patients) (p=0.00002); pattern 1 is characterized by disease onset 
and subsequent decline of activity, pattern 2 by chronic relapsing disease, and 
pattern 3 by chronic active disease. 
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Disease pattern were significantly different in the 3 groups (p 0.00002). In 
particular, pattern 1 was more frequently observed in the elderly (56.0%) and 
adults (57.1%) compared to young patients (41.0%) (p<0.0001 for both 
comparisons). Pattern 2 was more frequent in the younger patients (44.4%) 
compared to the elderly (p<0.002) and adults (p<0.0001) (31.9% and 31.2%, 
respectively), whereas pattern 3 was equally distributed in the 3 groups  (elderly: 
12.2%, adults: 11.7%, young subjects: 14.7%; p 0.458). 
 
3.3. Therapy at diagnosis and at follow-up 
Therapies at diagnosis and the need for different drug classes thereafter are 
shown in Table 4. Data are analyzed comparing pattern 1 vs. pooled pattern 2-3. 
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3.3.1. 5-ASA  
In the first two years from diagnosis, 5-ASA was prescribed equally in 
both pattern groups; only in the third year was 5-ASA significantly less frequently 
employed in the elderly, regardless of disease pattern. 
 
3.3.2 Steroids  
The use of systemic steroids was similar within the two pattern groups, 
except for pattern 1 in the first year (p 0.021), where a lesser steroid use was 
observed in adults. In patients with pattern 2-3, except for the first year from 
diagnosis, steroids were used 3 to 6-fold more frequently than in patient with 
pattern 1. The use of l.b.s was not statistically different in any year between the 
two pattern groups (data not shown). 
Response to systemic steroids after a first course is shown in Figure 3. 
The overall analysis of the three groups, irrespective of disease pattern showed 
similar remission rates across the groups, ranging from 32% to 45% at year 1 
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from diagnosis, and from 25% to 32% through year 2. No statistical differences 
were found.  
	
Figure 3. response to systemic steroids in the 3 study groups; syst.= systemic; 
LBS=low bioavailability steroids; worsening disease is defined by the need for IMM, 
BIO, or colectomy. 
 
3.3.3. Immunomodulators  
Out of 286 subjects receiving IMM during the study period, 253 (89%), 
received azathioprine, 29 subjects received 6-mercaptopurine (10%), and 5 were 
treated with methotrexate (1%) and, for statistical analysis, the treatments were 
pooled.  
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The analysis, stratified by disease pattern showed no differences for IMM 
prescription in the first year after diagnosis. Two and 3 years after diagnosis, in 
patient with pattern 1 and those with pattern 2-3, a significant lesser use of IMM 
was observed in the elderly and adults compared to young patients.  Moreover, the 
Kaplan-Meier curve analysis (Figure 4 A-B) confirmed that IMM were 
statistically significantly underused in the elderly and adults in both disease 
patterns. (pattern 1, p 0.0041; pattern 2-3, p 0.0034). 
 
Figure 4. Cumulative risk to be treated with IMM in UC patients with disease 
pattern 1 (A) and with disease pattern 2-3 (B). 
 
No differences were observed in terms of time-to-first IMM (Table 4). 
Treatment success was similar in the 3 groups (44.4% of patients in the elderly, 
36.7% in adults and 50% in younger patients).  
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3.3.4. Biologics  
All data refer to Infliximab, which was the only monoclonal antibody 
licensed for UC in Italy during the study period (adalimumab was used in 2 
patients as compassionate use for intolerance or no response to infliximab). In UC 
with pattern 1, BIO were equally prescribed in 2% of patients. In patients with 
combined pattern 2-3, BIO were more frequently prescribed in younger patients 
during the third year compared to the elderly and adults (p 0.005). Of note, during 
the third year, BIO prescription was 3-fold higher in younger subjects than in 
patients>40 years. There was no difference in median time-to-first prescription of 
BIO between the groups. 
 
3.4. Predictive factors for immunosuppression 
3.4.1. Risk factors for IMM treatment  
Univariate analysis (Table 5) showed that disease pattern 2-3, pancolitis, a 
more severe disease at onset and steroid use in the first year after diagnosis, were 
significantly associated to the use of IMM during the study period; whereas 
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higher age at diagnosis, higher CCI, chronic renal failure and multiple 
concomitant medications for comorbidities, were associated with lower use of 
IMM.  
 Univariate Multivariate 
Variable OR 95%CI p<value OR 95%CI p<value 
Extensive disease 1.994 1.592-2.499 0.0001 1.539 1.179-2.009 0.007 
Severe disease 1.275 1.024-1.588 0.030               - 
Pattern 2-3 4.294 3.138-5.876 <0.0001 3.724 2.647-5.238 0.0001 
Steroids in the first 
year 
5.095 3.731-6.956 <0.0001 3.592 2.553-5.054 0.0001 
Higher age at 
diagnosis 
0.977 0.970-0.984 <0.0001 0.979 0.963-0.994 0.007 
Charlson 
comorbidity index 
0.779 0.719-0.843 <0.0001               - 
Chronic renal failure 0.209 0.049-0.886 0.03               - 
Multiple  
co-medications 
0.864 0.759-0.982 0.025 1.234 1.001-1.520 0.049 
 
Table 5. Risk factors for treatment with immunomodulators. 
 
On multivariate analysis, only steroid use in the first year, disease pattern 
2-3, pancolitis at diagnosis, multiple concomitant medications and younger age at 
diagnosis were associated to IMM use. 
 
3.4.2. Risk factors for BIO treatment 
Disease pattern 2-3, use of steroids in the first year after diagnosis, use of 
IMM within the first year were significantly associated to the prescription of BIO 
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at univariate analysis (Table 6), whereas older age at diagnosis, higher CCI and 
co-medications, for concomitant diseases, were associated with lower 
prescription.  
 Univariate Multivariate 
Variable OR 95%CI p<value OR 95%CI p<value 
Pattern 2-3 14.973 6.471-34.649 <0.0001 10.791 4.603-25.294 <0.0001 
Steroids in the 
first year 8.650 4.558-16.416 <0.0001 4.553 2.314-8.958 <0.0001 
IMM in the first y 4.292 2.667-6.907 0.001 2.715 1.551-4.751 <0.0001 
Higher age at 
diagnosis 0.978 0.967-0.989 <0.0001 - 
Charlson 
comorbidity 
index 
0.717 0.625-0.824 <0.0001 0.649 0.458-0.919 0.015 
Multiple 
co-medications 0.742 0.579-0.950 0.018 - 
 
Table 6. Risk factors for treatment with BIO; IMM= immunomodulators 
 
On multivariate analysis only disease pattern 2-3, steroids or IMM used in 
the first year and a lower CCI were confirmed to be associated to BIO use. 
 
3.4.3. Need for colectomy 
Through the first 3 years from diagnosis, 58/1091 patients (5.3%) 
underwent colectomy.  Main indications were: refractory disease, fulminant 
disease and dysplasia or colon cancer (the latter only in the elderly and adults). 
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There was no difference between the three groups overall, but when analysed for 
disease patterns, every age group was more frequently operated on when 
presenting pattern 2-3 (p 0.016) (significance not included in table 4).  
 
3.4.4. Risk factors for surgery  
Patients with pattern 2-3, pancolitis, need for steroids, IMM or BIO in the 
first year from diagnosis were more likely to undergo colectomy through the 
follow-up period (Table 7); no protective factor was identified and all these 
parameters, except the use of IMM, were confirmed on multivariate analysis as a 
risk factor for colectomy.  
 Univariate Multivariate 
Variable OR 95%CI p<value OR 95%CI p<value 
Pattern 2-3 5.893 2.753-12.615 <0.0001 3.961 1.810-8.667 0. 001 
Extensive 
disease 2.121 1.347-3.338 0.001 1.685 1.028-2.760 0.038 
Steroids in the 
first year 4.008 2.099-7.654 <0.0001 2.195 1.067-4.514 0.033 
IMM in the 
first year 3.310 1.821-6.017 <0.0001 - 
BIO in the 
first year 12.571 5.830-27.106 <0.0001 5.932 2.528-13.922 <0.0001 
 
Table 7.  Risk factors for colectomy; IMM= immunomodulators; BIO= biologics 
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3.4.5. Diagnosis of malignancies in follow-up 
Malignancies occurring through the study period were stratified into three 
categories: 
1. colorectal cancer (CRC), including adenomas with high-grade dysplasia,  
2. extracolonic epithelial tumours,  
3. haemopoetic tumours.  
No differences in rates of malignancies were found in the 3 study groups, 
except for CRC, which was more frequent in the elderly (p 0.004). 
Exposure to IMM and BIO was not associated with malignancies in the 3 
study groups and this was confirmed at uni- and multivariate analysis. Advanced 
age at UC diagnosis (OR 1.026, 95%CI 1.006-1.047, p 0.012), concomitant 
diabetes (OR 3.228, 95%CI 1.327-7.852, p 0.01), concomitant chronic pulmonary 
disease (OR 3.538, 95%CI 1.176-10.643, p 0.025) and steroid use in the first year 
after diagnosis (OR 2.33, 95%CI 1.007-5.55, p 0.048) were found to be risk 
factors for malignancies at univariate analysis. 
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On multivariate analysis, advanced age at UC diagnosis remained the only 
risk factor significantly associated with malignancies (OR 1.022, 95%CI 1.001-
1.044, p 0.044). 
 
3.4.6. Deaths  
In the overall population, deaths occurred in 12/283 of the elderly (4%), 
12/285 (4%) of adults and 2/523 of younger patients (0.4%, p<0.0001). On 
univariate analysis, age ≥ 65 years (OR 1.064, 95%CI 1.035-1.095, p<0.0001), 
concomitant diseases (OR 1.836, 95%CI 1.429-2.361, p<0.0001), diabetes (OR 
3.983, 95%CI 1.691-9.382, p 0.002), pulmonary disease (OR 3.510, 95%CI 
1.167-10.559, p 0.025) and multiple co-medications for concomitant diseases (OR 
1.401, 95%CI 1.117-1.757, p 0.003) were significantly associated with death. On 
multivariate analysis, age ≥ 65 years at UC diagnosis remained the only risk factor 
(OR 1.059, 95%CI 1.029-1.089, p<0.0001). 
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4. DISCUSSION 
Disease course is usually thought to be milder in late-onset UC. Previous 
data show that only a minority of elderly patients require IMM for disease control 
[1, 28, 29]. In our large, multicenter Italian cohort, we showed for the first time 
that the disease pattern determined the need for more aggressive therapies and 
surgery also in late-onset UC patients, without clinically important differences 
compared to younger age groups. We limited the observation time from 2005 to 
2014 in order to include the period after the license of the first approved anti-TNF 
for UC in Italy (infliximab). Of note, although mild severity was the most 
frequent pattern of disease in late-onset UC patients, up to 44% presented with a 
behaviour which was not controlled by therapy. Moderate disease activity was the 
most frequent presentation at diagnosis in all groups, irrespective of the 
subsequent pattern of disease, as well as age at onset. Our study did not confirm a 
more aggressive onset compared to young patients, followed by prolonged 
remission in elderly UC patients as previously shown [30, 31], nor differences for 
response to steroids or IMM compared with younger age groups [6]. When the 
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entire cohort was analysed for steroids use, irrespective of disease pattern, we 
found that less than 50% of the elderly required steroids in the first year, 
decreasing to 20% in follow-up. This was consistent with the French cohort [1]. 
Interestingly, when we stratified the elderly population by disease patterns, the 
use of steroids was significantly higher in patterns 2-3, ranging from 60% in the 
first year to 40% in the third year. Despite disease pattern 2-3, we found that IMM 
were significantly less used in the elderly and adults than in younger patients, 
suggesting an undertreatment with IMM in such populations. This is confirmed by 
the univariate and multivariate analyses, which show that patients with disease 
patterns 2-3, requiring steroids in the first year, are more likely to receive IMM, 
but older age and concomitant disease that require multiple medications are the 
main limitation for their prescription. Similar data were found for the use of BIO. 
Our data reveal that safety concerns associated to older age would limit the use of 
effective medications in late-onset UC, rather than a milder course.  
We found that disease extension at onset was different from previous 
reports. In our cohort, the minority of patients (12%) presented with proctitis, 
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without age differences, compared to more than 30% in previous studies [1, 28, 
29]. Unfortunately, we could not assess the rate of disease progression in terms of 
colonic involvement over time. 
The overall need for surgery was lower than reported in literature [29, 32], 
since only 5% of the entire study population required colectomy through year 3, 
which was consistent with the results from a large Canadian cohort [32]. Major 
risk factors were represented by disease pattern 2-3 and extensive disease, 
together with the need for steroids and BIO in the first year, in line with former 
reports [1, 31], while age was not associated to different surgery rates, as also 
reported by Lakatos et al [28].  
Higher CCI was observed in the elderly, as expected, with figures roughly 
comparable with those reported by Ananthakrishnan et al [12]. Of note, our 
elderly cohort was much healthier than the one reported by Juneja et al. [26], 
probably due to different lifestyle factors and healthcare systems in Italy and in 
the US.  
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The occurrence of CRC was more frequent in the elderly, despite a shorter 
disease duration compared to high-risk populations usually requiring surveillance 
program [34], although a recent population-based study showed that CRC 
occurred earlier (median time 17 months) in late-onset UC [35]. 
The crude mortality rate in our cohort was 4.2% in the elderly, which is 
consistent with the IBSEN cohort [36]; most deaths were unrelated to UC in the 
elderly, but related to comorbidities and advanced age, whereas one fatality 
related to UC (sepsis after colectomy) was observed in a young patients.  
To our knowledge, this is the first large cohort study analyzing late-onset 
UC according to disease pattern. We found for the first time that late-onset UC 
patients presenting with patterns 2-3 are frequently undertreated most likely 
because of medical concerns. The limitations of this study derive mainly from the 
retrospective study design and lack of long-term follow-up.  
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5. CONCLUSION 
In conclusion, almost half of late-onset UC patients present an aggressive 
course, which is frequently undertreated. Therapeutic decisions regarding the 
elderly seem to be influenced by comorbidities and concomitant medications 
more than by disease severity. More studies on the therapeutic management of 
late-onset UC balancing clinical outcomes and safety concerns are needed in this 
particular setting.  
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